Osteoporosis Agents, Estrogenic

"Osteoporosis Agents, Estrogenic" is an administrative and descriptive categorization rather than a formally standardized single pharmacologic class in authoritative compendia

"Osteoporosis Agents, Estrogenic" is an administrative and descriptive categorization rather than a formally standardized single pharmacologic class in authoritative compendia

"Osteoporosis Agents, Estrogenic" is an administrative and descriptive categorization rather than a formally standardized single pharmacologic class in authoritative compendia It generally encompasses therapies that exert estrogen-receptor agonist activity on skeletal tissue, most notably systemic estrogens and selective estrogen receptor modulators (SERMs) such as raloxifene and bazedoxifene These agents function primarily by binding to estrogen receptors in bone, thereby inhibiting osteoclast-...

It generally encompasses therapies that exert estrogen-receptor agonist activity on skeletal tissue, most notably systemic estrogens and selective estrogen receptor modulators (SERMs) such as raloxifene and bazedoxifene

These agents function primarily by binding to estrogen receptors in bone, thereby inhibiting osteoclast-mediated bone resorption, slowing skeletal turnover, and helping maintain bone mineral density

Clinically, these medications are primarily utilized for the prevention and treatment of postmenopausal osteoporosis and related fracture risk reduction, often in individuals who also have menopausal vasomotor symptoms or elevated breast cancer risk